Adiponectin is well recognized as plasma physiologically active polypeptide hormone exclusively derived from human and animal mature adipocytes, with vigorous property in antidiabetic, antiobesity, antiatherogenic, and anti-inflammatory processes. In this study, we investigated the correlation between serum adiponectin level and clinical and pathological parameters in patients with chronic hepatitis C (CHC). The study included 127 patients with CHC and 42 healthy volunteers as controls whose laboratory parameters and serum adiponectin and tumor necrosis factor-α (TNF-α) were assessed using enzyme-linked immunosorbent assay (ELISA). We demonstrated that a lower serum adiponectin level was associated with male gender, higher γ-glutamyltransferase (γ-GGT), higher albumin, higher TNF-α, and steatosis grade. The higher level of serum adiponectin in patients with genotype 2a was demonstrated when compared with that in the patients with genotype 1b. Furthermore, of great interest, results suggested that the significant differences regarding viral genotype seemed to occur only in male patients with CHC but not in female patients. In conclusion, serum adiponectin was associated with gender, genotype, liver steatosis, and TNF-α in a Chinese population with CHC.
Hepatitis C Chronic Adiponectin Genotype Steatosis Gender
This is a preview of subscription content, log in to check access.
This work was supported by funding from the Beijing Science and Technology Committee (2004054) to Qing-Hua Meng.
Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes. 2007;56:1712–1717. doi:10.2337/db06-1665.PubMedCrossRefGoogle Scholar
Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369–1377. doi:10.1016/j.jacc.2006.06.053.PubMedCrossRefGoogle Scholar
Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240–2243. doi:10.1210/jc.2004-1266.PubMedCrossRefGoogle Scholar
Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol. 2005;100:2717–2723. doi:10.1111/j.1572-0241.2005.00311.x.PubMedCrossRefGoogle Scholar
Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. 2006;24:1349–1357. doi:10.1111/j.1365-2036.2006.03114.x.PubMedCrossRefGoogle Scholar
Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. 2007;46:66–73. doi:10.1002/hep.21703.PubMedCrossRefGoogle Scholar
Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930–936. doi:10.1053/jhep.2002.32150.PubMedCrossRefGoogle Scholar
Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med J. 2004;27:855–868.PubMedGoogle Scholar
Kara B, Gunesacar R, Doran F, Kara IO, Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv Ther. 2007;24:972–982. doi:10.1007/BF02877701.PubMedCrossRefGoogle Scholar
Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load : impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28:9–16. doi:10.2165/00044011-200828010-00002.PubMedCrossRefGoogle Scholar
Dal Pero F, Tang KH, Gerotto M, et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis. 2007;196:998–1005. doi:10.1086/521306.PubMedCrossRefGoogle Scholar
Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275–282. doi:10.1016/j.jhep.2005.09.015.PubMedCrossRefGoogle Scholar
Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat. 2006;13:371–376. doi:10.1111/j.1365-2893.2005.00697.x.PubMedCrossRefGoogle Scholar
Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629–2640.PubMedGoogle Scholar